Biotech Values

[donotknowityet]

On YMI

Aeroleaf final phase II results were indicated for end of January or February in the last CC.

Tesmilifene third interim look also expected by this time frame.
Dew,
For warning signs you listed trials in third world countries.
That applies to Tesmilifene. Can you give specific reason why I this canbe a problem? Obviously it is very cheap to do it that way. And there must be some reason why not evreybody does it that way.
But I do not understand what are the concrete problems.
Enlightment is appreciated. Tia.
---

Of course the best way to minimize the risk is to have a drug invented in third wrorld country like Nimotuzimab of YMI.
The Cubans have retained their rights to the third world, and partnered with YMI for the advanced countries.
Now Nimo is approved in Cuba, India, China, etc. and there are extensive human data for all imaginable indication.

YMI knows everything about how the drug works, and they do not need animal models, and theory to decide which indications to go after, using what cotreatments, etc.